Posttransplant acute limbic encephalitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:163921G04.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Posttransplant acute limbic encephalitis (PALE) is a rare neurological complication that occurs following allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by acute inflammation of the limbic system — the brain structures involved in memory, emotion, and behavior, including the hippocampus, amygdala, and surrounding temporal lobe regions. The condition typically manifests within the first few months after transplantation and is believed to be related to immune-mediated mechanisms, potentially involving donor-derived immune cells reacting against the recipient's central nervous system, though the exact pathogenesis remains incompletely understood. Some cases have been associated with human herpesvirus 6 (HHV-6) reactivation. Key clinical features include acute onset of confusion, short-term memory loss, seizures (often temporal lobe epilepsy), disorientation, personality changes, and emotional disturbances. Brain MRI typically reveals characteristic signal abnormalities in the medial temporal lobes, particularly the hippocampi, on T2-weighted and FLAIR sequences. Cerebrospinal fluid analysis may show mild pleocytosis and elevated protein levels. The condition can progress rapidly and may lead to significant cognitive impairment if not promptly recognized and treated. Treatment approaches are largely empirical due to the rarity of the condition and include antiviral therapy (particularly when HHV-6 reactivation is suspected), immunosuppressive agents such as corticosteroids, and anticonvulsant medications for seizure management. Outcomes are variable; some patients may recover partially or fully, while others experience persistent neurological deficits, particularly memory impairment. Early recognition and intervention are considered important for improving prognosis. There are currently no standardized treatment guidelines, and management is typically individualized based on the suspected underlying etiology and clinical severity.

Also known as:

Clinical phenotype terms— hover any for plain English:

EEG with focal epileptiform dischargesHP:0011185CSF polymorphonuclear pleocytosisHP:0012756ViremiaHP:0020071HyperglycorrhachiaHP:0031885CSF lymphocytic pleiocytosisHP:0200149EEG with abnormally slow frequenciesHP:0011203
Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Posttransplant acute limbic encephalitis.

View clinical trials →

No actively recruiting trials found for Posttransplant acute limbic encephalitis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Posttransplant acute limbic encephalitis community →

No specialists are currently listed for Posttransplant acute limbic encephalitis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Posttransplant acute limbic encephalitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Posttransplant acute limbic encephalitisForum →

No community posts yet. Be the first to share your experience with Posttransplant acute limbic encephalitis.

Start the conversation →

Latest news about Posttransplant acute limbic encephalitis

No recent news articles for Posttransplant acute limbic encephalitis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Posttransplant acute limbic encephalitis

What is Posttransplant acute limbic encephalitis?

Posttransplant acute limbic encephalitis (PALE) is a rare neurological complication that occurs following allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by acute inflammation of the limbic system — the brain structures involved in memory, emotion, and behavior, including the hippocampus, amygdala, and surrounding temporal lobe regions. The condition typically manifests within the first few months after transplantation and is believed to be related to immune-mediated mechanisms, potentially involving donor-derived immune cells reacting against the recipient's cen

At what age does Posttransplant acute limbic encephalitis typically begin?

Typical onset of Posttransplant acute limbic encephalitis is adult. Age of onset can vary across affected individuals.